In 2024, workers are reporting double-digit declines in feelings of belonging and connectedness at work, according to an Oct. 1 report from Businessolver, which offers benefits and HR technology solutions. The major declines have occurred even as employees acknowledge that corporate diversity, equity, inclusion and belonging (DEIB) efforts are becoming more visible, the report found.
“There’s no better place to meet our industry partners in person and get a first-hand feel for the state of the pharma industry than at CPHI,” says Borderless Partner Rosalie Harrison, who leads the firm’s life sciences practice.
The chemical industry is at a turning point. Executive leaders must navigate rising costs, stringent regulations, and increasing competition while seizing opportunities in sustainability. With major players like the ADNOC Group acquiring European assets to embrace sustainable technologies, the industry is shifting toward renewable feedstocks, circular economies, and decarbonization.
On Sep. 25, German biopharma company Boehringer Ingelheim opened its new 11,000 sqm Angelika Amon Research Building at its site in Vienna, Austria. According to Boehringer Ingelheim, the investment of around €60 million is further proof of the company’s commitment to cancer research.
Eli Lilly and Company (Lilly) recently announced a $4.5 billion (€4.07 billion) investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development. The facility will enable Lilly to research new methods of producing medicines and scale up manufacturing for clinical trials.
